Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer
This real-world study demonstrated the comparable efficacy of durvalumab plus chemotherapy to the TOPAZ-1 trial for patients with advanced BTC and identified prognostic factors. There was a trend toward improved efficacy with higher durvalumab dosing (1000-1500 mg) vs lower dosing, though further research is needed to confirm this relationship.
Authors
- Hung‐Chih Hsu (ORCID: https://orcid.org/0000-0002-4719-4143)
- Wen‐Kuan Huang (ORCID: https://orcid.org/0000-0001-7789-8347)
- Wen‐Chi Chou (ORCID: https://orcid.org/0000-0002-0361-4548)
- San‐Chi Chen (ORCID: https://orcid.org/0000-0002-9436-5400)
- Nai‐Jung Chiang (ORCID: https://orcid.org/0000-0003-2743-9702)
- Chia‐Hsun Hsieh (ORCID: https://orcid.org/0000-0002-5547-409X)
- Po‐Jung Su (ORCID: https://orcid.org/0000-0002-6228-9650)
- Yan-Jei Tang (ORCID: https://orcid.org/0000-0002-7597-9909)
- Chun‐Nan Yeh (ORCID: https://orcid.org/0000-0003-1455-092X)
- Ming‐Huang Chen (ORCID: https://orcid.org/0000-0003-3187-7393)
- Chiao‐En Wu (ORCID: https://orcid.org/0000-0002-1900-2984)
- Ming-Mo Hou
- Jen-Shi Chen
Institutions
- National Yang Ming Chiao Tung University (TW)
- Chang Gung University (TW)
- Taipei Veterans General Hospital (TW)
- Taipei Municipal YangMing Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
- Taipei City Hospital (TW)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1093/oncolo/oyae306
- Citations
- 7
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Chang Gung Medical Foundation